Skip to content

Promore – Reports and prospectus

Interim Reports (Promore) November 29, 2022 Interim report January – September 2022 Report (pdf)
Interim Reports (Promore) August 30, 2022 Promore Pharma Interim report January – June 2022 Report (pdf)
Interim Reports (Promore) May 17, 2022 Promore Pharma — interim report January-March 2022 Report (pdf)
Interim Reports (Promore) February 16, 2022 Interim report January – December 2021 Report (pdf)

MESSAGE FROM THE CEO

Read what our CEO has to say about our business.

BUSINESS MODEL

The RespiraSense™ business model consists of several components that together create a complete delivery that generates attractive gross margins and recurring revenues.

VISION

To avoid preventable respiratory failure events by transforming the standard of care in patient monitoring.

MISSION

To become the de facto standard-of-care for monitoring respiratory compromised patients in Europe and the US.